AbbVie (ABBV) and privately held X-Chem have entered into a multi-target drug discovery partnership with the aim of identifying novel small molecule inhibitors of promising new targets in addition to those already validated but difficult to address. AbbVie has an exclusive option to license active hits and leads generated during the collaboration and is responsible for all further development and commercialization. Financial terms of the deal have not been disclosed.